Newsletter Subject

Neoadjuvant Chemo-IO Promising in Borderline Resectable Pancreatic Cancer

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Wed, Apr 10, 2024 10:47 PM

Email Preheader Text

Daily Headlines Wednesday, April 10, 2024 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLIGH

[MEDPAGE TODAY]( Daily Headlines Wednesday, April 10, 2024 Today's Top Stories for {NAME} [MEETING COVERAGE]( [Neoadjuvant Chemo-IO Promising in Borderline Resectable Pancreatic Cancer]( [ENDOCRINOLOGY]( [Study Assuages Thyroid Cancer Fears With GLP-1 Receptor Agonists]( [CARDIOLOGY]( [Shockwave Therapy Shows Benefit in Lower Limb Claudication]( THE BREAK ROOM [Spell Check-Up: Try to Pass This Spelling Quiz]( CME SPOTLIGHT [Uncovering the Under-Diagnosed in MDS: The MDS Diagnostic Accelerator Hub]( [MEETING COVERAGE]( [Bispecific Checkpoint Inhibitor Improves Survival in Advanced Gastric/GEJ Cancer]( [NEUROLOGY]( [Brain Injury More Severe From Falls at U.S.-Mexico Border Wall]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [SPECIAL REPORTS]( [SPAC Activity Should Be Monitored Amid Corporatization of Healthcare]( CME SPOTLIGHT [Optimizing Anemia Management in Patients With Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia Through Shared Decision-Making]( [NEUROLOGY]( [Early Minimally Invasive Removal of Intracerebral Hemorrhage Shows Benefit]( [SPECIAL REPORTS]( [Cass Review Finds Weak Evidence for Puberty Blockers, Hormones in Youth Gender Care]( [SPECIAL REPORTS]( [PAs in Oregon Can Soon Use 'Physician Associate' Title]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Navigating CAR T-Cell Therapy for Non-Hodgkin Lymphoma in Community Practice]( [MEETING COVERAGE]( [Immunotherapy After Definitive Therapy Flops in Head and Neck Cancer]( [PSYCHIATRY]( [FDA OKs Anxiety Stimulation Device; Long-Term KarXT Data; Psilocybin Adverse Events]( [PERSPECTIVES]( [Bad Surgeon: Barriers to Addressing Medical Misconduct]( CME SPOTLIGHT [Expert Insight Into von Hippel-Lindau (VHL) Disease: From Symptoms and Diagnosis to Cutting-Edge Therapies and Adverse Event Management]( [PUBLIC HEALTH & POLICY]( [Biden Admin Imposes National Limits on 'Forever Chemicals' in Drinking Water]( [MEETING COVERAGE]( [FFR-Guided Complete Revascularization Did Not Improve Outcomes in MI Patients]( [PULMONOLOGY]( [After Massive CPAP Recall, Philips Ordered to Overhaul Manufacturing]( CME SPOTLIGHT [Employing Collaborative Care Strategies for the Management of Pediatric Patients With Hodgkin Lymphoma]( [AAD READING ROOM]( [Acne, Benzoyl Peroxide, and Benzene: An Expert Weighs In]( [OB/GYN]( [Arizona Can Enforce 1864 Law Criminalizing Nearly All Abortions, Court Says]( [PUBLIC HEALTH & POLICY]( [More Health Systems Likely to Drop Out of Medicare Advantage, Analyst Predicts]( CME SPOTLIGHT [Expert Insights and System-Based Care Trends in Early-Stage NSCLC and Melanoma, Metastatic Bladder Cancer, and Relapsed/Refractory Follicular Lymphoma]( [OPHTHALMOLOGY]( [No Difference in Kidney Failure Risk Between Three Anti-VEGF Agents for Eye Disease]( # Weekly Survey [Worried About Avian Flu in Humans?]( A farmworker exposed to dairy cattle in Texas contracted highly pathogenic avian influenza A, although the [CDC says the risk to human health is low]([VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2024-04-10&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

26/05/2024

Sent On

26/05/2024

Sent On

25/05/2024

Sent On

24/05/2024

Sent On

24/05/2024

Sent On

24/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.